Who We Are

Poseida was established in 2015 as a spinout from parent company Transposagen, an early leader in the development of gene engineering technologies, also led by our founding CEO, Eric Ostertag, M.D., Ph.D. Dr. Ostertag, the first graduate of the University of Pennsylvania’s gene therapy program, is a pioneer in the field of cell and gene therapies.

In 2017 the company presented pre-clinical data demonstrating tumor response in its first CAR-T product candidate, P-BCMA-101 in multiple myeloma, followed soon after by pre-clinical data for P-PSMA-101 in prostate cancer showing potent anti-tumor activity and persistent, durable responses. In December 2017, Poseida received a grant from The California Institute for Regenerative Medicine (CIRM) to support the Phase 1 clinical trial for P-BCMA-101. The first BCMA patient in the trial was dosed later that year.

Poseida completed a financing round in the spring of 2018 and later received an additional grant from CIRM to support our preclinical studies for P-PSMA-101 in prostate cancer. In November 2018, we received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration for P-BCMA-101 for the treatment of multiple myeloma and Orphan Drug designation in the year following.

We dosed the first patient in a Phase 1 clinical trial of our second product candidate, P-PSMA-101, in May 2020. Poseida completed a crossover financing round just prior to an initial public offering (IPO) in July 2020, going public on the Nasdaq under the ticker symbol PSTX. The company is currently listed on the Russell 2000 Index and the Nasdaq Biotech Index (NBI).

In 2021, the U.S. Food and Drug Administration cleared the Investigational New Drug (IND) application for Poseida’ s first fully allogeneic CAR-T product candidate, P-BCMA-ALLO1 for the treatment of multiple myeloma. We presented strong CAR-T data in a solid tumor indication with our P-PSMA-101 program. In October 2021, we announced a strategic collaboration with Takeda focused on developing non-viral in vivo gene therapy programs utilizing our proprietary genetic engineering platform technologies.

We are looking forward to advancing our programs in CAR-T and in gene therapies, including an off-the-shelf allogeneic CAR-T in BCMA and another in MUC1C, our first solid tumor product candidate with multiple potential targets. In addition to our pipeline of CAR-T product candidates across liquid and solid tumors, we are focused on developing gene therapies to treat rare diseases.